Get started
Fennec Pharmaceuticals Inc.Fennec Pharmaceuticals Inc.Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

FENC chart


Full chart

FENC upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪119.15 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
126.28
Basic EPS (TTM)
0.10 USD
Net income (FY)
‪−16.34 M‬ USD
Revenue (FY)
‪21.64 M‬ USD
Shares float
‪20.28 M‬
Beta (1Y)
0.35

Employees


Employees (FY)
29
Change (1Y)
−7 −19.44%
Revenue / Employee (1Y)
‪746.27 K‬ USD
Net income / Employee (1Y)
‪−563.42 K‬ USD

About Fennec Pharmaceuticals Inc.


Sector
Health Technology
CEO
Jeffrey S Hackman
Headquarters
Durham
Website
fennecpharma.com
Founded
1996
FIGI
BBG000DTH814
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

FENC news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where FENC is featured.

See all sparks 

Frequently Asked Questions


The current price of FENC is 4.65 USD — it has decreased by −0.46% in the past 24 hours. Watch Fennec Pharmaceuticals Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Fennec Pharmaceuticals Inc. stocks are traded under the ticker FENC.
FENC stock has fallen by −6.26% compared to the previous week, the month change is a −8.63% fall, over the last year Fennec Pharmaceuticals Inc. has showed a −34.41% decrease.
We've gathered analysts' opinions on Fennec Pharmaceuticals Inc. future price: according to them, FENC price has a max estimate of 22.00 USD and a min estimate of 13.00 USD. Watch FENC chart and read a more detailed Fennec Pharmaceuticals Inc. stock forecast: see what analysts think of Fennec Pharmaceuticals Inc. and suggest that you do with its stocks.
FENC reached its all-time high on Apr 9, 2018 with the price of 14.99 USD, and its all-time low was 0.04 USD and was reached on Mar 3, 2009. View more price dynamics on FENC chart.
See other stocks reaching their highest and lowest prices.
FENC stock is 8.37% volatile and has beta coefficient of 0.35. Track Fennec Pharmaceuticals Inc. stock price on the chart and check out the list of the most volatile stocks — is Fennec Pharmaceuticals Inc. there?
Today Fennec Pharmaceuticals Inc. has the market capitalization of ‪145.75 M‬, it has increased by 0.42% over the last week.
Yes, you can track Fennec Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
Fennec Pharmaceuticals Inc. is going to release the next earnings report on Nov 7, 2024. Keep track of upcoming events with our Earnings Calendar.
FENC earnings for the last quarter are −0.20 USD per share, whereas the estimation was −0.03 USD resulting in a −700.00% surprise. The estimated earnings for the next quarter are −0.09 USD per share. See more details about Fennec Pharmaceuticals Inc. earnings.
Fennec Pharmaceuticals Inc. revenue for the last quarter amounts to ‪7.30 M‬ USD, despite the estimated figure of ‪11.05 M‬ USD. In the next quarter, revenue is expected to reach ‪8.99 M‬ USD.
FENC net income for the last quarter is ‪−5.55 M‬ USD, while the quarter before that showed ‪12.78 M‬ USD of net income which accounts for −143.44% change. Track more Fennec Pharmaceuticals Inc. financial stats to get the full picture.
No, FENC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 29.00 employees. See our rating of the largest employees — is Fennec Pharmaceuticals Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Fennec Pharmaceuticals Inc. EBITDA is ‪5.70 M‬ USD, and current EBITDA margin is −60.09%. See more stats in Fennec Pharmaceuticals Inc. financial statements.
Like other stocks, FENC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Fennec Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Fennec Pharmaceuticals Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Fennec Pharmaceuticals Inc. stock shows the sell signal. See more of Fennec Pharmaceuticals Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.